前收市價 | 6.00 |
開市 | 6.70 |
買盤 | 9.80 |
賣出價 | 11.80 |
拍板 | 120.00 |
到期日 | 2024-07-19 |
今日波幅 | 5.92 - 6.70 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 125 |
DexCom (DXCM) announces expansion of its AID partnership in the Netherlands to offer an easier diabetes management experience.
Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.
Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That’s because Dexcom (NASDAQ:DXCM) delivered stronger-than-expected third-quarter results in October. And during its Q3 earnings call, Dexcom actually reported that when diabetes patients are on the GLP-1 drugs, their demand for glucose monitors tend to rise. Dexcom and other diabetes stocks advanced significantly over the subsequent six months or so, but they